Interferon Lambda Therapy for COVID-19

Phase 2 Withdrawn Icahn School of Medicine at Mount Sinai Eiger BioPharmaceuticals · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this research study is to test the safety and effectiveness of an investigational drug peginterferon lambda-1a in treating COVID-19.

Timeline

Start: 2020-09
Primary completion: 2021-02-05
Completion: 2021-02-05

Outcome

Outcome not reported

Stopped (Enrollment): “Due to the number of competing trials at their site, the study team has closed enrollment and withdrawn this trial.”

Publications

Lee JS, Shin EC. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020 Oct;20(10):585-586. doi: 10.1038/s41577-020-00429-3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Peginterferon Lambda-1a	Protein / enzyme biologic	180 ug	Subcutaneous